Acumen Pharmaceuticals (ABOS) Interest & Investment Income (2021 - 2026)

Acumen Pharmaceuticals (ABOS) has 5 years of Interest & Investment Income data on file, last reported at $1.1 million in Q1 2026.

• For the quarter ending Q1 2026, Interest & Investment Income fell 56.94% year-over-year to $1.1 million; the trailing twelve-month figure through Mar 2026 stood at $6.0 million (down 52.75% YoY), and the FY2025 full-year result was $7.4 million, down 47.98% from the prior year.
• Interest & Investment Income declined to $1.1 million in Q1 2026, from $1.3 million in the prior quarter.
• In the past five years, Interest & Investment Income ranged from a high of $4.0 million in Q1 2024 to a low of $1.1 million in Q1 2026.
• A 4-year average of $2.6 million and a median of $2.7 million in 2024 frame the typical range for Interest & Investment Income.
• Across the five-year window, Interest & Investment Income jumped 102.55% in 2024 and tumbled 56.94% in 2026, its largest moves.
• Tracing ABOS's Interest & Investment Income over 4 years: stood at $4.0 million in 2023, then retreated by 24.27% to $3.0 million in 2024, then tumbled by 55.82% to $1.3 million in 2025, then decreased by 19.52% to $1.1 million in 2026.
• Business Quant data shows ABOS's Interest & Investment Income at $1.1 million in Q1 2026, $1.3 million in Q4 2025, and $1.6 million in Q3 2025.